In a Drosophila model of Alzheimer's disease, jatamansinol mitigates human tau-induced neurotoxicity by reducing reactive oxygen species (ROS) levels and boosting antioxidant enzyme activity in Tau protein-expressing cells. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.